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Nevirapine, a nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse tran-
scriptase, was administered for the first time to humans in a pilot study designed to investigate the
pharmacokinetics and tolerance of the drug following single-dose administration to 21 HIV-1-infected
individuals. The study followed a parallel design. Different groups of three subjects each were given one of
seven dose levels (2.5 to 400 mg) in sequential order, starting with the lowest dose. Each subject received only
one dose. Nevirapine was rapidly absorbed at all doses from a tablet formulation. Peak concentrations in
plasma were generally achieved within 90 min of dose administration. Secondary peaks were also noted
between 3 and 12 h or between 24 and 28 h, the latter being noted mainly in subjects receiving the higher doses.
After 24 h, concentrations in plasma declined in a log-linear fashion. The terminal half-life and mean residence
time exceeded 24 h in all but one subject, indicating a prolonged disposition time in this population. Both peak
concentrations in plasma and areas under the plasma concentration-time curves increased proportionally with
increasing dose from 2.5 to 200 mg; however, the increase in the peak concentration in plasma and the area
under the plasma concentration-time curve appeared to be less than proportional at the 400-mg dose level in
this small number of subjects. This observation may be due to increased clearance or decreased absorption at
the highest dose or population differences in absorption or clearance between doses. Studies with a cross-over
design are planned to resolve these issues. The pharmacokinetic characteristics of nevirapine are appropriate
for once-daily administration. A daily 12.5-mg dose is predicted to achieve trough concentrations in plasma in
the range required to totally inhibit replication of wild-type HIV-1 in human T-cell culture.
Nevirapine, formerly known as BI-RG-587, is a potent
nonnucleoside reverse transcriptase inhibitor specific for
human immunodeficiency virus type 1 (HIV-1) (7) which
shows good characteristics for development as a potential
therapeutic agent. The 50% inhibitory concentration (IC50)
in human T-cell culture is 10.6 mg/ml (40 nM) and the
therapeutic index is 8,000 (6). Nevirapine in combination
with zidovudine exhibits synergistic antiviral activity with-
out increased cytotoxicity (11). The structure of nevirapine
is shown in Fig. 1. It is a low-molecular-weight compound
which is lipophilic (partition coefficient = 83) and a weak
base (pKa = 2.8). It is highly soluble at pH <3, but its
aqueous solubility decreases to approximately 0.1 mg/ml at
neutral pH.
Studies in chimpanzees demonstrated high bioavailability
(64%) and a long half-life (t4/2; 11 to 24 h) (4), and studies in
rats indicated even distribution throughout the body, includ-
ing the brain (8). The plasma:cerebrospinal fluid distribution
ratio in two cynomolgus monkeys 2 h after oral administra-
tion of 20 mg/kg of body weight was 0.4; in these same
animals plasma:brain distribution ratios were 0.8 and 1.4,
respectively. In vitro protein binding studies with rat and
human plasma showed that plasma protein binding was 51
and 62%, respectively. In vitro metabolism experiments with
liver microsomes from humans, rats, monkeys, and dogs
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showed hydroxylation at several sites, the major oxidative
metabolite being hydroxymethyl-nevirapine. In chimpanzee,
rat, and dog, the urinary excretion of parent drug was low,
suggesting liver metabolism as the major route of clearance.
Induction of cytochrome P-450 2B1 (phenobarbital-induc-
ible) and 3A (alcohol-inducible) isozymes occurred in rats
after repeated dosing at 10 mg/kg and higher (2). However,
short-term safety studies in rats and dogs showed no toxic-
ities which would preclude development of the compound.
The objectives of the present study were to generate initial
information on nevirapine pharmacokinetics and dose pro-
portionality and to assess the safety and tolerance of single
rising doses in subjects with HIV-1 infection. These data
could then be used to determine initial dose, schedule, and a
dose escalation scheme for a multiple-dose clinical study of
nevirapine. For ethical reasons, our goal for the multiple-
dose trial was to achieve concentrations in plasma even at
the lowest dose levels which could be expected to provide
complete inhibition of reverse transcriptase on the basis of
cell culture data.
A few months after this single-dose study was completed
and after initiation of multiple-dose trials, results of cell
culture experiments which showed rapid development of
resistance to nonnucleoside reverse transcriptase inhibitors,
including nevirapine, were reported (9, 12, 13). This phe-
nomenon was confirmed in the initial clinical trials in HIV-
1-infected persons treated with these compounds (10). Ne-
virapine inhibits the most common mutant reverse
transcriptase enzyme (Tyr-181 to Cys) with an IC50 of 700
ng/ml (2.6 ,uM), compared with an IC50 of 10.6 ng/ml (0.04
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FIG. 1. Nevirapine, 5,11-dihydro-11-cyclopropyl-4-methyl-6H-di-
pyrido-[3,2-b2',3'e][1,4]diazepin-6-one (molecular weight, 266.302).
,uM) for the wild-type enzyme. As a result of these observa-
tions, clinical studies have been redesigned to target higher
concentrations of nevirapine in plasma in the hopes of
inhibiting variant virus with reduced susceptibility to the
compound.
MATERIALS AND METHODS
The participants were HIV-1-infected persons with abso-
lute CD4 counts of <400/,u. The volunteers were 18 men and
3 women ranging in age from 19 to 46 years. Six volunteers
had AIDS, and 10 had AIDS-related complex; their CD4
counts ranged from 0 to 379 (mean + standard deviation, 191
± 124). By transmission category, there were 12 homosexual
males, 2 homosexual males who also used intravenous
drugs, and 7 intravenous drug users. Three individuals were
Latino and one was African-American. The University of
Massachusetts Medical School Human Subjects Committee
reviewed and approved the study and the document which
all participants signed to provide informed consent.
Three persons receiving each dose level were studied
simultaneously. Doses were 2.5, 12.5, 25, 50, 100, 200, and
400 mg given as tablets containing 2.5, 12.5, or 50 mg of
nevirapine. Table 1 shows the doses achieved in terms of
milligrams per kilogram for individuals in each cohort.
Concomitant medications were kept to a minimum, and
drugs with known interactions with phenobarbital were
required to be stopped 28 days prior to the trial, as were any
investigational agents. Zidovudine was continued until 7
days before the trial and was resumed upon its completion.
A urine specimen for drug screening was collected at the
time of admission to hospital for the study. Participants
fasted overnight under observation and received a single
dose of nevirapine after initial blood sampling the following
morning.
Blood for determination of nevirapine levels in plasma was
drawn at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 28,
and 32 h after dosing. An electrocardiograph was obtained at
2 h postdosing. Volunteers were discharged from the hospi-
tal after the 32-h blood draw. Blood for repeat determination
of nevirapine levels in plasma were drawn at 48 and 72 h,
since preclinical studies suggested a complete plasma nevi-
rapine concentration-time curve could be obtained within
this time frame. After administration of the 12.5-mg dose, it
became apparent that nevirapine clearance in humans was
lower than that predicted from studies in animals, so addi-
tional plasma samples were collected at 96 h and between
168 and 200 h when possible.
Plasma was separated promptly, stored at -80°C, and
assayed by high-pressure liquid chromatography (HPLC)
after inactivating the virus by heating at 56°C for 30 min. The
assay was validated for precision and accuracy and is linear
from 25 to 10,000 ng/ml (5). Extraction recovery was greater
than 88% of the spiked amounts at all concentrations for
both nevirapine and the internal standard. Extracted drug-
free human plasma samples demonstrated the absence of any
interfering or coeluting components. A total of 25 standard
curves were used during analysis of the study samples. The
coefficient of variation of the slopes of the curves as deter-
mined from unweighted linear regression was 3.4%. Six
different concentrations of quality control standards run
during the study had intraday and interday relative standard
deviations ranging from 4.6 to 12.4%, and the deviation from
the nominal value was 9.7% or less. The limit of quantita-
tion, defined as the lowest standard with a relative standard
deviation of <15%, was 25 ng/ml.
The area under the plasma concentration-time curve
(AUC) was calculated by the linear trapezoidal rule method.
The relationships of AUC and the peak concentration of
nevirapine in plasma (Cm.) with dose were examined by
linear and quadratic least-squares regression of the AUC or
Cmaxdata versus dose. The quadratic term was required to
be statistically significant at the 0.05 level to be accepted as
evidence of deviation from linearity.
Apparent oral clearance was estimated from the ratio of
the dose administered to the observed AUC. The apparent
volume of distribution at steady state was calculated from
the ratio of dose-adjusted area under the moment curve to
AUC. t1/2 was estimated by linear regression of log plasma
nevirapine concentration-versus-time data. The datum
points included in the regression analysis of the terminal
elimination phase were determined from visual inspection of
graphic semilogarithmic plots of the data. Steady-state
plasma nevirapine concentrations, assuming once-daily dos-
ing, were calculated for each individual from the ratio of
AUC to the dosing interval. Trough concentrations pre-
dicted to be achieved at steady state were estimated from the
individual average steady-state concentrations, individual
t112s, and the dosing interval chosen for initial multiple-dose
studies (24 h) (3).
RESULTS
Pharmacokinetics. Individual semilogarithmic plots of
plasma nevirapine concentration-time course data after ad-
ministration of single doses of 12.5, 200, and 400 mg of
nevirapine are shown in Fig. 2A to C, respectively. The first
time point used in the linear regression for calculation of the
t112 for each individual is shown by the dashed line. For the
majority of the subjects, six or nine datum points were
included in the regression analysis. Only four datum points
were available for estimation of the t112 of nevirapine in
subject 16 (200-mg dose level). All subjects had detectable
levels of nevirapine in plasma after administration of the
lowest (2.5-mg) dose, but the majority of the concentrations
were below the linear range of the assay, precluding further
pharmacokinetic analysis. Concentrations in the plasma of
all other subjects at all time points in the study were above
the limit of quantitation of the assay.
Noncompartmental pharmacokinetic parameters are listed
for individual subjects in Table 1. The drug was rapidly
absorbed; substantial amounts of nevirapine were present in
the systemic circulation as early as 15 min after the tablets
were ingested. The time-concentration profiles observed
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were characterized by an initial early concentration peak
occurring at a mean of 2.2 h (0.5 to 6 h) after dose
administration; this was followed by a concentration plateau
which concluded in a secondary concentration maximum at
a mean of 14 h in many subjects. There was a bimodal
distribution of secondary maxima which occurred either
between 3 and 12 h or between 24 and 28 h. The secondary
maximum tended to occur during the later time frame at the
higher dose levels. Visual inspection of semilogarithmic
plots of the concentration-versus-time data revealed that, in
most subjects, the concentration plateau extended to ap-
proximately 24 h, after which time nevirapine concentrations
declined in a log-linear fashion.
AUC and Cmax increased with increasing dose. It should
be noted that, in some cases, a large portion of the AUC (and
mean residence time) was extrapolated because of the lack
of samples obtained at later time points. Greater than 20% of
the calculated AUCs were extrapolated for two of three
TIME (hours)
FIG. 2. Plasma nevirapine concentration-time courses after ad-
ministration of 12.5-mg (A), 200-mg (B), and 400-mg (C) single doses
in HIV-1-infected volunteers. The dashed lines are placed at the first
time points used in the linear regression analysis for calculation of
t1/2. Drug concentrations were determined by a validated HPLC
method which was linear from 25 to 10,000 ng/ml.
subjects in the 25- and 50-mg dose cohorts; however, in the
12.5-, 100-, 200-, and 400-mg dose cohorts, substantial
extrapolation occurred in calculating the AUC for only one
of three subjects at most. Figure 3A illustrates the relation-
ship between AUC and dose. The AUC increased propor-
tionally with respect to dose over the dosing range of 12.5 to
100 mg. At higher doses there appeared to be deviation from
linearity, especially in the 200- to 400-mg dosage increment,
in which a 2-fold increase in dose resulted in only a 1.2-fold
increase in the AUC. Regression analysis showed that both
linear and quadratic terms were statistically significant in
modeling the AUC-dose relationship (P < 0.001 and P <
0.01, respectively). For the quadratic fit, the parameter
estimate for the linear term was 0.994 (standard error [SE] =
0.096), the estimate for the quadratic term was -0.00145 (SE
= 0.000269), and the adjusted r2 was 0.952 for a no-intercept
model. For the linear fit, the parameter estimate was 0.498
(SE = 0.045), and the adjusted r2 was 0.873 for a no-intercept
model. The no-intercept model was used because predose
concentrations in plasma were less than the limit of quanti-
tation. Figure 3B shows the relationship between Cmax and
dose. As with AUC, both the linear and the quadratic terms
were statistically significant (P < 0.001 and P < 0.05,
respectively). For the quadratic fit, the parameter estimate
for the linear term was 0.013 (SE = 0.001), the estimate for
the quadratic term was -0.0000139 (SE = 0.0000033), and
the adjusted r2 was 0.973 for a no-intercept model. For the
linear fit, the parameter estimate was 0.0085 (SE = 0.00047)
and the adjusted r2 was 0.947 for a no-intercept model.
Mean apparent oral clearance was 0.39 ml/kg/min in this
small population of subjects. The t112 ranged from 22 to 84 h,
with a harmonic mean of 40 h. Mean residence time averaged
69 h. The mean apparent volume of distribution was 1.37
liters/kg.
Adverse events. No serious adverse events occurred. Two
subjects at the 2.5-mg dose and one subject each at the 12.5-,
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TABLE 1. Individual noncompartmental pharmacokinetic
parameters after single doses of nevirapine in
HIV-1-infected subjectsa
Dose (mg) CL'/
and subject AUCQO Cm" Tma, tl2 MRT p V.,/F (liters/
no. (dosage (pLg. hr/ml) (ng/ml) (h) (h) (h) (ml/kg kg)
[mg/kg]) mmn'
2.5
1 (0.03) <25
2 (0.03) 40
3 (0.04) 30
12.5
4 (0.17) 10.23 113 0.75 77 103 0.30 1.86
5 (0.18) 6.04 157 0.75 35 49 0.48 1.41
6 (0.18) 4.71 166 1.5 24 34 0.63 1.31
25
7 (0.38) 27.34 325 0.50 51 80 0.23 1.13
8 (0.48) 14.56 589 0.50 28 40 0.55 1.33
9 (0.49) 40.02 334 4 84 125 0.20 1.54
50
10 (0.63) 46.20 646 1 54 73 0.30 1.33
11 (0.77) 63.82 584 6 73 100 0.20 1.21
12 (0.84) 29.78 451 4 44 67 0.35 1.42
100
13 (1.39) 98.33 1,021 3 60 89 0.24 1.27
14 (1.39) 89.76 910 8 58 82 0.26 1.27
15 (1.62) 86.45 1,714 0.5 44 62 0.31 1.16
200
16 (2.05) 150.53 1,534 0.5 70 113 0.23 1.54
17 (3.93) 89.01 2,148 1.5 22 34 0.77 1.57
18 (4.13) 167.06 2,529 4 37 56 0.39 1.30
400
19 (4.89) 204.56 3,385 28 34 52 0.43 1.35
20 (4.92) 168.85 2,952 1.5 31 48 0.49 1.25
21 (5.33) 127.44 2,868 3 25 38 0.64 1.49
a AUC,,, area under the plasma nevirapine concentration-versus-time
curve from time zero to infinity; Cmn, maximum concentration in plasma;
Tm:, time to maximum concentration in plasma; t1/2, half-life; MRT, mean
residence time; CLp/F, apparent oral clearance; VsJF, apparent volume of
distribution at steady state.
200-, and 400-mg doses had headaches, all of which were
mild. One person was noted to sleep during the day after the
200-mg dose but denied subjective somnolence, and no
sedative effect was seen in any of the three recipients of the
highest dose (400 mg). Two persons had gastrointestinal
disturbances after the 12.5-mg dose; one of these individu-
al's family members were also suffering similar symptoms. A
single subject had tachycardia and confusion 6 to 16 min
after ingestion of the 2.5-mg dose and subsequently com-
plained of fatigue, irritability, and headache.
In summary, there was no dose-response relationship with
any adverse event, and none were judged as probably or
definitely caused by the drug. In comparison with pretreat-
ment values, there were no meaningful changes in routine
clinical laboratory test results obtained at 96 or 168 h
postdosing (Table 2).
DISCUSSION
This report describes the first administration of nevirapine
to humans. Nevirapine in single doses up to 400 mg by
250
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FIG. 3. (A) Area under the plasma nevirapine concentration-
time curve as a function of weight-adjusted dose, showing least-
squares linear and quadratic regression lines. (B) Nevirapine Cm as
a function of dose, showing least-squares linear and quadratic
regression lines. *, observed; ---, predicted, linear; , pre-
dicted, quadratic.
mouth was well tolerated. Peak concentrations in plasma
exceeded the IC50 of nevirapine for the wild-type reverse
transcriptase enzyme at all doses tested and for the Tyr-181
to Cys mutant at the three highest doses (100, 200, and 400
mg).
The profiles of the plasma nevirapine concentration-ver-
sus-time curves demonstrated a plateau at approximately
80% of the peak concentration that lasted about 24 h. This
profile was not observed in animal pharmacokinetic studies,
but it may be explained by enterohepatic recycling, as
occurs in rats (8) and as suggested by the presence of a
secondary concentration maximum. Alternatively, the rates
of absorption and elimination over this period may be
similar, thus balancing each other out. The first possibility
can be excluded if the plateau does not occur following
TABLE 2. Laboratory tests
Mean + SD
Test (units) 96-168 h
Predose postdose
Leukocyte (cellS/mm3) 4,400 + 2,100 4,600 - 1,800
Hemoglobin (g/dl) 13.30 + 1.70 13.40 ± 1.70
Platelet count (103/mm3) 220.8 ± 58.3 207.6 + 66.30
Serum creatinine (mg/dl) 0.9 ± 0.2 0.9 ± 0.2
Alanine aminotransferase (U/liter) 43.4 ± 32.9 42.5 ± 31.4
Bilirubin (mg/dl) 0.6 ± 0.4 0.7 ± 0.5
Alkaline phosphatase (U/liter) 76.3 ± 14.3 76.3 ± 13.7
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intravenous administration of nevirapine, but these data are
not yet available.
The failure of the AUC to increase proportionately from
the 200- to 400-mg dose may simply be a result of the small
number of subjects and their variable health status, but it
also raises the question of saturation of absorption or en-
hanced clearance at higher doses. Calculation of absorption
potential at the various dose levels by the method of Dress-
man et al. (1) predicts decreased absorption at the 400-mg
dose compared with that at the lower doses. Support for the
possibility of enhanced clearance comes from the rapid
induction of cytochrome P-450 2B1 observed in rats chron-
ically dosed with nevirapine (2). The maintenance of rela-
tively high concentrations in plasma during the plateau phase
could result in hepatic enzyme induction at the highest dose
even during the course of a single-dose study.
It is clear that nonlinear Michaelis-Menten kinetics do not
occur when single oral 12.5- to 400-mg doses of nevirapine
are administered, since Michaelis-Menten kinetics would
lead to an upward rather than a downward curvature of the
AUC-versus-dose plot. The dose linearity of nevirapine will
be studied in detail by using larger numbers of subjects and
steady-state dosing in a future trial.
The apparent volume of distribution calculated in humans
is consistent with the values observed in rats, dogs, mon-
keys, and chimpanzees. It is also consistent with fairly even
distribution throughout all organs and tissues within the
body. Observed apparent oral clearance, t112 (mean, >24 h),
and mean residence time are similar to values obtained in
chimpanzees (4) but not other species.
One of the objectives of the trial described here was to
provide information for planning dosing levels and regimens
for a rising-multiple-dose tolerance, pharmacokinetic, and
activity study. In a chronic-dosing trial of nevirapine, we
would hope to achieve trough concentrations in plasma of
approximately 25 times the IC50 in human T-cell culture (40
nM) (6) using a dosing interval which would facilitate com-
pliance. Therefore, predicted accumulation to average and
trough steady-state nevirapine concentrations were calcu-
lated for once-daily dosing assuming linear accumulation (3)
and the individual tl2s observed in the present study. A daily
dose of 12.5 mg was predicted to produce trough concentra-
tions in plasma at steady state of 13 to 36 times the IC50 and
was chosen for the initial dose level. A fourfold dose
escalation scheme, i.e., 50 and 200 mg, in succeeding co-
horts should achieve trough levels in plasma of approxi-
mately 100 to 225 and 250 to 540 times the IC50, respectively.
The accuracy of these predictions and the ability to maintain
the desired levels in plasma will be assessed in multiple-dose
studies.
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